Long event-free survival after anti-BCMA CAR-T cell treatment for relapsed and refractory multiple myeloma patients: Two case reports

INTRODUCTION: Chimeric antigen receptor T (CAR-T) cells targeting B-cell maturation antigen (BCMA) have been used in the treatment of relapsed and refractory multiple myeloma (RRMM). The response rate and the depth of responses induced by anti-BCMA CAR-T cells are impressive. However, despite this,...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Jinhuan, Ming, Xi, Wang, Chunyan, Xu, Bi, Xiao, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
3700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104258/
https://www.ncbi.nlm.nih.gov/pubmed/33950974
http://dx.doi.org/10.1097/MD.0000000000025784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104258/
https://www.ncbi.nlm.nih.gov/pubmed/33950974
http://dx.doi.org/10.1097/MD.0000000000025784

Ejemplares similares